LLY
Eli Lilly and Company
LLY has the edge over STIM overall, supported by lower modeled downside and stronger fundamentals.
STIM
Neuronetics, Inc.
STIM's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STIM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
STIM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STIM PE Valuation
STIM has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STIM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STIM on earnings quality, reporting a profit while its opponent remains loss making.
STIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | +$0.50 |
| Q2 2026 | -$0.44 | +$0.70 |
| Q1 2026 | -$0.54 | +$0.78 |
| Q4 2025 | -$0.59 | +$0.79 |
| Q3 2025 | -$0.83 | +$0.38 |
| Q2 2025 | -$1.14 | -$0.04 |
| Q1 2025 | -$1.32 | -$0.38 |
| Q4 2024 | -$1.38 | -$0.33 |
STIM is still losing money, but far less than before: $0.33 per share over the past year, against $1.87 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STIM on profitability, with a higher operating margin.
STIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42M | +13% |
| Q2 2026 | $41.6M | +9.1% |
| Q1 2026 | $34.5M | +7.8% |
| Q4 2025 | $41.8M | +86% |
| Q3 2025 | $37.3M | +101% |
| Q2 2025 | $38.1M | +132% |
| Q1 2025 | $32M | +84% |
| Q4 2024 | $22.5M | +11% |
STIM has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | +21 points |
| Q2 2026 | -3.6% | +18 points |
| Q1 2026 | -26% | +8.3 points |
| Q4 2025 | -12% | +39 points |
| Q3 2025 | -20% | +22 points |
| Q2 2025 | -21% | +31 points |
| Q1 2025 | -34% | +4.9 points |
| Q4 2024 | -51% | -29 points |
STIM's operating margin was 1.3% last quarter, up 21 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STIM on cash generation, producing positive trailing cash flow while its opponent burns cash.
STIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $768K | +$1.7M |
| Q2 2026 | -$1.4M | +$2.3M |
| Q1 2026 | -$9.6M | +$7.6M |
| Q4 2025 | $692K | +$9.4M |
| Q3 2025 | -$899K | +$4.9M |
| Q2 2025 | -$3.8M | +$1.8M |
| Q1 2025 | -$17.2M | -$4.8M |
| Q4 2024 | -$8.7M | -793% |
STIM has burned cash in almost every quarter: −$10M over the past year, against −$31M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.3% | +3.9M shares |
| 1 year | +14% | +9.7M shares |
| 3 years | +169% | +48.4M shares |
| 5 years | +197% | +51.1M shares |
| Available history | +313% | +58.4M shares |
STIM has 77M diluted shares, up 14% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STIM Net Leverage
STIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 17.8 | Oversold |
STIM's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STIM PE vs Healthcare Sector
STIM has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STIM on trend strength, trading above more of its moving averages.
STIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.11 | 32% below |
| 20 week MA | $2.29 | 38% below |
| 50 week MA | $1.82 | 21% below |
| 100 week MA | $2.57 | 44% below |
| 200 week MA | $2.47 | 42% below |
STIM is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STIM on returns for 2026, with the stronger performance.
STIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.50 | $10.7 | +137% |
| 2021 | $10.7 | $4.60 | -57% |
| 2022 | $4.60 | $5.97 | +30% |
| 2023 | $5.97 | $2.90 | -51% |
| 2024 | $2.90 | $1.48 | -49% |
| 2025 | $1.48 | $1.42 | -4.1% |
| 2026 YTD | $1.42 | $1.43 | +0.7% |
STIM has finished three years in a row lower, and it's up 0.7% so far in 2026.